Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Gilead Sciences
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Infection with HCV genotype 2 or 3
Had cirrhosis determination
Prior treatment failure
Screening laboratory values within defined thresholds
Subject had not been treated with any investigational drug or device within 30 days of the screening visit
Use of highly effective contraception methods if female of childbearing potential or sexually active male
You may not be if
Prior exposure to an direct-acting antiviral targeting the HCV nonstructural protein (NS)5B polymerase
Pregnant or nursing female or male with pregnant female partner
Current or prior history of clinical hepatic decompensation
History of clinically significant illness or any other major medical disorder that may have interfered with subject treatment, assessment or compliance with the protocol
Excessive alcohol ingestion or significant drug abuse
Clareo Health | Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (FUSION)
